Park Ha Biological Technology Company Limited (PHH) - Short-Term Debt to Capital

Geopolitical tensions and mutual trade barriers between Beijing and the West are hindering dietary supplement exports, which negatively impacts the revenues of the retailer Park Ha Biological Technology (PHH). This chart shows the market price, valued at 0.01, which serves as an indicator of the business's resilience, relying on moderately cyclical demand within the Chinese healthcare sector. Park Ha Biological Technology (PHH) complements its operations with standard environmental initiatives regarding packaging recycling and the procurement of organic components.

This indicator assesses financial stability by comparing liabilities with a maturity of up to one year against equity to determine the business's degree of dependence on external financing. Current debt under one year relative to equity at 0.01 is critical for Park Ha Biological Technology (PHH), as revenue instability during the promotion of cosmetic brands increases liquidity risks when servicing short-term loans.